Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment Plan of the HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor

NCT04100694 is registered in ClinicalTrials.gov with Merus B.V. as lead sponsor.

NCT NCT04100694
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04100694 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment Plan of the HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
Lead sponsor
Merus B.V.
Phase
Expanded access
Overall status
Approved for marketing
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, cholangiocarcinoma, colorectal cancer, head and neck cancer, non small cell lung cancer, nrg1 fusion, pancreatic cancer, prostate cancer, renal cell carcinoma, solid tumor, unspecified, adult, unknown primary tumors